Q2 2025 Astrana Health Inc Earnings Call Transcript
Key Points
- Astrana Health Inc (ASTH) reported strong financial results for Q2 2025, with total revenues of $654.8 million, representing a 35% year-over-year growth.
- The company successfully transitioned 78% of its revenue into full risk contracts, up from 60% a year ago, indicating strategic alignment and growth.
- Astrana Health Inc (ASTH) closed the acquisition of Prospect Health at a reduced price of $708 million, improving its leverage position to 2.7 times net debt to adjusted EBITDA.
- The company reaffirmed its full-year 2025 revenue guidance of $3.1 to $3.3 billion and adjusted EBITDA guidance of $215 to $225 million.
- Astrana Health Inc (ASTH) maintained strong profitability and cash flow generation, with a free cash flow conversion expected to be between 40% to 45% of adjusted EBITDA for the full year.
- Medicaid revenue, which constitutes 28% of the company's total revenue, faces potential headwinds due to policy changes, with a conservative estimate of a 20% to 25% decline in enrollment.
- The company anticipates a slightly higher medical cost trend for the second half of the year due to the Prospect acquisition, which could impact overall profitability.
- Astrana Health Inc (ASTH) is pausing large-scale M&A activities until it meets its leverage targets, potentially limiting growth opportunities through acquisitions.
- The company faces challenges in integrating Prospect Health, with a focus on achieving $12 to $15 million in synergies over the next 12 to 18 months.
- Astrana Health Inc (ASTH) has limited exposure to health insurance exchanges, but potential subsidy changes could still pose a risk to a small portion of its revenue.
Good day everyone and welcome to today's Astrana Health second-quarter 2025 earnings call. (Operator Instructions)
Today's speakers will be Brandon Sim, President and Chief Executive Officer of Astrana Health; and Chan Basho, Chief Operating and Financial Officer. The press release announcing Astrana Health Inc.'s results for the second quarter ended March 31, 2025, is available at the investors section of the company's website at www.astranahealth.com.
The company will discuss certain non-gap measures during this call. Reconciliations to the most comparable GAAP measures are included in the press release to provide some additional background on its results, the company has made a supplemental deck available on its website. A replay of this broadcast will also be made available at Astrana Health website after the conclusion of this call.
Before we get started, I would like to remind everyone that this conference call and any accompanying information discussed here and contain certain forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
